Claims

1. Composition comprising a cellulase or a lipolase or a savinase or an enzymatic cocktail chosen from associations lipolase and savinase, amylase and savinase, savinase and mannanase, DNase and mannanase, DNase and lipolase, DNase and savinase, DNase and cellulase, Dispersin B and cellulase, Dispersin B and cellulase and DNase and least one microbicidal molecule chosen from the group composed of fluoroquinolones, glycopeptides, lipoglycopeptides, fusidic acid, penicillins, cephalosporins, carbapenems, monobactams, polymyxins, beta-lactams, macrolides, lincosamides, oxazolidinones, amphenicols, tetracyclines, aminoglycosides, rifamycins, nitrofurans, sulphonamides, nitroimidazoles antifungals (echinocandins, fluorocytosines, azoles, griseofulvins), lytic enzymes (for example endolysins or lysozyme), N-acetylcysteine, quaternary ammonium, biguanides, amines, halogenated derivatives (particularly of chlorhexidine), antimicrobial peptides, silver (Ag) derivatives, H_2O_2 derivatives, peroxy acids, phenolic derivatives, aldehydes, alcohols and mixtures thereof as combination products, for simultaneous use, separated use or use staggered over time, for use in the preventative and/or curative treatment of infections in the tissues, bones and cartilage and/or the internal mucosa of the body at an implantation site, said infections being post-implantation infections of mammalian bodies, in particular post-implantation infections of the human body.
2. Composition for use according to claim 1, wherein said enzymatic cocktail further comprises one or several enzymes chosen from the group composed of deoxyribonucleases (DNases), lipases, proteases and polysaccharide hydrolases including Dispersin B and cellulase.
3. Composition for use according to claim 1 or 2, wherein each enzyme is present in a concentration ranging between 0.01 and 1000mg/L.
4. Composition for use according to any one of claims 1 to 3, wherein said at least one microbicidal molecule chosen from the group composed of fluoroquinolones, glycopeptides, lipoglycopeptides, fusidic acid, penicillins, cephalosporins, carbapenems, monobactams, polymyxins, beta-lactams, macrolides, lincosamides, oxazolidinones, amphenicols, tetracyclines, aminoglycosides, rifamycins, nitrofurans, sulphonamides, nitroimidazoles antifungals (echinocandins, fluorocytosines, azoles, griseofulvins), lytic enzymes (for example endolysins or

lysozyme), N-acetylcysteine, quaternary ammonium, biguanides, amines, halogenated derivatives (particularly of chlorhexidine), antimicrobial peptides, silver (Ag) derivatives, H_2O_2 derivatives, peroxy acids, phenolic derivatives, aldehydes, alcohols and mixtures thereof is present in a concentration ranging between 0.01 and 1000mg/L.

5. Composition for use according to any one of claims 1 to 4, said composition being in the form of a sterile aqueous solution which may be injected or not, which may be diluted or not in water for injectable preparation or in the form of a soluble powder, preferably in the form of a lyophilisate.
6. Composition for use according to any one of claims 1 to 5, said post-implantation infections of mammalian bodies, in particular of the human body, being post-implantation infections of Staphylococcus aureus bacteria, Staphylococcus epidermis bacteria, Escherichia coli bacteria, Escherichia faecalis bacteria, Klebsiella pneumoniae bacteria and Pseudomonas aeruginosa bacteria.
7. Composition for use according to any one of claims 1 to 6, said post-implantation infections of mammalian bodies, in particular of the human body, being infections localised at an implantation site of an implantable medical device, for example a tube, a catheter or a prosthesis.
8. Composition for use according to any one of claims 1 to 7, intended to kill at least 1 Log10, preferably at least 2 Log10, preferentially at least 5 Log10 of the microorganisms responsible for post-implantation infections of mammalian bodies, in particular in the human body.
9. Use of a composition comprising at least one enzyme and at least one microbicidal molecule as combination products, for simultaneous use, separated use or use staggered over time, for the treatment, at an implantation site, of post-implantation infections of mammalian bodies, in particular in the human body.
10. Use of a composition comprising at least one enzyme and at least one microbicidal molecule according to claim 9, by injection, by infiltration, by irrigation, by ingestion or by percutaneous application.
11. Method for treating, at an implantation site, post-implantation infections of mammalian bodies, in particular in the human body, with a composition comprising at least one enzyme and at least one microbicidal molecule as combination products, for simultaneous use, separated use or use staggered over time, said method comprising the following steps:

- administration, at an implantation site of an implantable medical device, of a composition comprising at least one enzyme and at least one microbicidal molecule,
- breakdown, by action of said at least one enzyme of said administered composition, of a biofilm present at said implantation site of said implantable medical device, and
- destruction of bacteria and/or inhibition of the growth of bacteria released from said biofilm, by action of said at least one microbicidal molecule of said administered composition.

12. Method for treating post-implantation infections of mammalian bodies, in particular in the human body, according to claim 11, wherein said administration is carried out by injection, by infiltration, by irrigation, by ingestion or by percutaneous application.